SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($0.66), $0.17 worse than the analyst estimate of ($0.49).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

Earnings

Goldman Sachs Starts Sage Therapeutics (SAGE) at BuyMay 15, 2015 7:02 AM Sage Therapeutics (SAGE) PT Raised to $70 at Leerink Partners as New Data Corroborates Prior Promising ResultsMay 14, 2015 11:03 AM SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial ResultsMay 14, 2015 6:30 AM SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial ResultsMay 14, 2015 6:30 AM SAGE Therapeutics (SAGE) Issues Positive Update on SAGE-547; Primary Endpoint MetMay 14, 2015 6:18 AM SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status EpilepticusMay 14, 2015 6:15 AM SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status EpilepticusMay 14, 2015 6:15 AM